Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) received a $11.00 target price from Canaccord Genuity in a research note issued on Tuesday, October 24th. The firm currently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity’s price target indicates a potential upside of 90.64% from the stock’s current price.
Several other brokerages also recently issued reports on AUPH. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Vetr upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $7.35 price target for the company in a research report on Tuesday, September 19th. Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 price target on shares of Aurinia Pharmaceuticals in a research report on Monday, October 23rd. Finally, Seaport Global Securities reiterated a “buy” rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Aurinia Pharmaceuticals has an average rating of “Buy” and a consensus price target of $10.79.
Aurinia Pharmaceuticals (NASDAQ AUPH) opened at $5.77 on Tuesday. Aurinia Pharmaceuticals has a 1-year low of $2.02 and a 1-year high of $10.54.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.10. The business had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 28.61% and a negative net margin of 16,648.93%. research analysts predict that Aurinia Pharmaceuticals will post -1.01 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Aurinia Pharmaceuticals Inc (AUPH) Given a $11.00 Price Target by Canaccord Genuity Analysts” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/12/canaccord-genuity-analysts-give-aurinia-pharmaceuticals-inc-auph-a-11-00-price-target.html.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its stake in shares of Aurinia Pharmaceuticals by 1.1% during the second quarter. Bank of New York Mellon Corp now owns 81,950 shares of the biotechnology company’s stock worth $502,000 after buying an additional 931 shares during the last quarter. Royal Bank of Canada grew its stake in shares of Aurinia Pharmaceuticals by 8.6% in the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,341 shares during the last quarter. Nicholas Investment Partners LP grew its stake in shares of Aurinia Pharmaceuticals by 1.0% in the second quarter. Nicholas Investment Partners LP now owns 254,084 shares of the biotechnology company’s stock worth $1,557,000 after purchasing an additional 2,484 shares during the last quarter. UBS Group AG grew its stake in shares of Aurinia Pharmaceuticals by 13.6% in the first quarter. UBS Group AG now owns 112,314 shares of the biotechnology company’s stock worth $824,000 after purchasing an additional 13,405 shares during the last quarter. Finally, FMR LLC grew its stake in shares of Aurinia Pharmaceuticals by 0.3% in the second quarter. FMR LLC now owns 5,867,800 shares of the biotechnology company’s stock worth $35,969,000 after purchasing an additional 19,200 shares during the last quarter. 27.73% of the stock is currently owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.